Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms, Glandular and Epithelial 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasms 1Liver Neoplasms 1Liver Diseases 1Digestive System Neoplasms 1Digestive System Diseases 1Carcinoma, Hepatocellular 1Carcinoma 1Adenocarcinoma 1

Interventions

ponatinib 2napabucasin 2Irinotecan 2Imatinib Mesylate 2Gemcitabine 2130-nm albumin-bound paclitaxel 2pralsetinib 1pembrolizumab 1nilotinib 1linifanib 1ibritumomab tiuxetan 1bosutinib 1Vorinostat 1Temozolomide 1Sorafenib 1Rituximab 1Pemetrexed 1Paclitaxel 1Melphalan 1Leucovorin 1Fluorouracil 1FANG vaccine 1Etoposide 1Cytarabine 1Cisplatin 1Carmustine 1Carboplatin 1Bortezomib 1Bevacizumab 1BID protein, human 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Neoplasms by Histologic Type × linifanib × Clear all
NCT01009593 2012-09-10

Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)

Abbott

Phase 3 Terminated
1,035 enrolled
Gastrointestinal

Adenocarcinoma, Carcinoma, Digestive System Diseases, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡